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Previewsone question that remains to be
answered is whether the effect on b cell
insulin secretion plays any role in this
effect, given that hyperinsulinemia is a
potential causal factor in cancer growth
and metastases. Any effect of insulin on
tumor growth would most likely require
chronic hyperinsulinemia, and this would
be associated with insulin resistance.
The FGFR4-R385 knockin mice demon-
strated increased insulin secretion in
response to glucose, but no change in
insulin sensitivity. Thus, whether the
increased risk of cancer with the
FGFR4-R388 polymorphism is due to
increased insulin secretion remains to
be determined, as this polymorphism
seems to be protective against diabetes.
The FGFR receptor isoforms have diver-
gent signaling properties in different
tissues; therefore, the FGFR4-R388 poly-
morphism may have other signaling
effects in the tumor tissue, possibly
directly increasing IR signaling in tumor
cells, as seen in b cells in vitro. Similarly,
this polymorphism was shown to affect
b cells in the mouse model. Unless the
polymorphism also affected additional
peripheral metabolic tissues, such as
muscle and adipocytes, how would this
explain the improved insulin sensitivity insome of the human studies? Another
unanswered question is how the single
nucleotide polymorphism actually affects
the function of the FGFR4 receptor. While
alterations in amino acid sequences have
been shown to inhibit or enhance recep-
tor function via alterations in substrate
binding and activation, this was not un-
dertaken in the present study. These
types of studies will certainly help both
in understanding the underlying patho-
physiology and in the consideration of
potential drug targets.
The exciting results from Ezzat et al.
(2013) demonstrate the application of
cell culture and mouse models to deter-
mine the mechanisms through which
polymorphisms identified in human
population studies can lead to disease.
This study completes the circle by return-
ing to human studies to examine whether
the in vitro and animal findings are
applicable to human populations and
also raises many questions for future
investigation.REFERENCES
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The mechanisms underlying the biological activity of metformin, a widely prescribed drug to treat type 2
diabetes, remain elusive. In a recent issue ofCell,Cabreiro et al. report that inC. elegans,metformin indirectly
impacts lifespan by altering the methionine metabolism of its microbial partner E. coli (Cabreiro et al., 2013).Metformin is a widely prescribed oral
antihyperglycemic agent of the biguanide
family recommended as first-line therapy
for type 2 diabetes. One generally
accepted mechanism for metformin ac-
tion is a mild and transient inhibition of
hepatocyte mitochondrial respiratory-
chain complex-1, which restricts thehepatic gluconeogenic program (Viollet
and Foretz, 2013). Despite its prom-
inence on the antidiabetic drug market,
the exact mechanism of metformin action
has not been fully elucidated. Its impact
on hepatic gluconeogenesis has been
linked to the decrease of cellular energy
status, which activates the cellularmetabolic sensor AMP-activated protein
kinase (AMPK). Recent studies have,
however, challenged this view, revealing
the importance of other AMPK-indepen-
dent mechanisms (Miller et al., 2013).
Metformin biological activity goes beyond
its current therapeutic usage as it has
been also shown to reduce the risk of17, June 4, 2013 ª2013 Elsevier Inc. 809
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Figure 1. Metformin Slows Aging inC. elegans byMetabolic Alteration of Its TrophicMicrobial Partner, E. coli, in a Strain-DependentManner
(A) Metformin disrupts the bacterial folate cycle, which alters bacterial methionine metabolism. Upon feeding on drug-altered E. coli, the wormmethionine meta-
bolism is altered and triggers a metabolic dietary restriction phenomenon as well as activation of AMPK, which together slow worm aging by yet unknownmech-
anisms. In addition, direct toxicity of metformin on worms is buffered via an AMPK- and SKN-1-dependent activation of a detoxification response.
(B) The effects of metformin on worm lifespan are strongly dependent upon its trophic partner. Metformin impact on worm lifespan combines both direct and
indirect effects, i.e., drug toxicity versus bacterial strain-specific lifespan extension. The influence of metformin on lifespan depends on whether the direct or
indirect effect predominates.
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Previewscancer (Dowling et al., 2011) and delay
aging in animal models such as rodents
(Anisimov et al., 2011) and the nematode
Caenorhabditis elegans (Onken and Dris-
coll, 2010). Again, the underlying mecha-
nisms are unclear, but studies suggest
that metformin recapitulates the effects
of dietary restriction, known to improve
lifespan and/or healthspan of a variety of
animals. In C. elegans, metformin treat-
ment extends lifespan and increases
healthspan via AMPK, suggesting that
metformin engages an AMPK-dependent
metabolic loop conserved across phyla
(Onken and Driscoll, 2010). In a follow-
up study recently published in Cell, Cab-
reiro et al. reveal that metformin indirectly
extendsC. elegans lifespan by altering the
metabolism of E. coli, its microbial trophic810 Cell Metabolism 17, June 4, 2013 ª2013partner (Cabreiro et al., 2013) (see
Figure 1).
Central to the study by Cabreiro et al. is
the observation that, in worms, metformin
is rather toxic and does not extend life-
span in the absence of their live trophic
partner, the E. coliOP50 strain (Cabreiro
et al., 2013). This detrimental effect is
observed either in axenic condition (i.e.,
strict germ-free setting) or upon feeding
of the worms on dead E. coli, therefore
establishing that active E. coliOP50 meta-
bolism mediates lifespan extension upon
metformin treatment. The authors then
identified the bacterial folate metabolic
pathway as a key player in the lifespan
effect of metformin, making three obser-
vations: First, a genetic variant of the
OP50 strain mutated for a folate cycleElsevier Inc.enzyme lacks the ability to promote life-
span extension upon metformin treat-
ment; then metformin treatment markedly
changed the folate’s composition in
OP50; and finally, pharmacological inhibi-
tion of the bacterial folate cycle mimics
metformin treatment. Despite showing
the importance of the microbial folate
metabolic pathway in the metformin
response, the authors did not observe
significantly modified folate levels in the
worms. Subsequently, they obtained
several key results that mapped the
metabolic effect of metformin at the level
of the methionine cycle, a folate-
associated pathway. They first identified
strong perturbations in the bacterial
methionine cycle upon metformin treat-
ment, consistent with reduced microbial
Cell Metabolism
Previewsmethionine production. Using a
C. elegans methionine synthetase mutant
incapable of producing methionine in the
worm, they further showed that metformin
lifespan extension was strongly
enhanced. Finally, they identified altered
levels of methionine-related metabolites
(S-adenosylmethionine and S-adenosyl-
homocystein) in C. elegans, suggesting a
disrupted methionine cycle linked
to reducedmicrobial methionine availabil-
ity. S-adenosylmethionine synthase
(SAMS-1) inhibition had already been
linked to lifespan extension in C. elegans
via an unknown mechanism shared with
eating-impaired dietary restriction mu-
tants (Hansen et al., 2005). A previous
study showed that metformin effect on
lifespan extension is abrogated in these
mutants (Onken and Driscoll, 2010). Simi-
larly, Cabreiro et al. showed that in
sams-1 mutants metformin-induced life-
span extension is lost, suggesting that
both metformin and dietary restriction
mutation act by disrupting methionine-
associated functions.
Onken and Driscoll (2010) had previ-
ously found that metformin-induced life-
span extension requires AMPK. Cabreiro
et al. further demonstrated that the
longevity effect of metformin is also
dependent on the stress resistance acti-
vator SKN-1, which induces the expres-
sion of glutathione-S-transferase-4, a
detoxification gene, in an AMPK-depen-
dent manner. Through a worm growth in-
hibition assay, the authors demonstrated
that AMPK and SKN-1 protect worms
against metformin toxicity. SKN-1-
dependent gst-4 expression was also
observed in worms fed on another E. coli
strain (HB101), which does not sustain
metformin lifespan extension, suggestingan uncoupling of E. coli-mediated
lifespan extension and SKN-1 drug detox-
ification activity. The authors directly
addressed this hypothesis by selectively
probing AMPK and SKN-1 importance in
E. coli-mediated lifespan extension by
metformin, independently of their function
in drug detoxification. In an elegant assay
using worms fed with metformin-
pretreated E. coli, the authors revealed
that only AMPK deficiency altered the life-
span extension phenotype in this setting.
This result demonstrated that AMPK-
dependence of lifespan extension bymet-
formin is partly due to resistance against
drug toxicity via SKN-1 activation and
partly to AMPK involvement in the bacte-
ria-mediated effects on the worm.
Collectively, this study reports how
metformin slows aging in C. elegans
by metabolic alteration of its trophic mi-
crobial partner, E. coli. The deep mecha-
nistic resolution of the study in both the
worm and its bacterial partner reveals
that metformin disrupts the bacterial
folate cycle, which in turn reduces the
levels of S-adenosylmethionine in the
worm, slowing its aging by both
metabolic ‘‘dietary’’ restriction-like
phenomenon and AMPK activation
(see Figure 1). Obvious mechanistic
questions remain to be elucidated, such
as how metformin impacts folate cycle
in the bacteria and, on the worm side,
how AMPK activation and metabolic
‘‘dietary’’ restriction mediate lifespan
extension. Nevertheless, the important
message is that the effects of metfor-
min on worm lifespan are strongly
dependent upon its accompanying
microbe. Indeed, metformin impact on
worm is the sum of both direct and indi-
rect effects, i.e., drug toxicity versusCell Metabolismmicrobe-mediated lifespan extension,
with the actual influence of metformin on
lifespan depending on whether the direct
or indirect effect predominates (see
Figure 1).
The C. elegans/E. coli trophic associa-
tion, although not a host/microbiota asso-
ciation per se in the absence of an
obvious colonization pattern of the host
by E. coli, is an excellent model providing
a mechanistic framework of how a drug
impacts the influence of microbial meta-
bolism on the physiology of its eukaryote
partner. This theme is of particular rele-
vance to the host/microbiota field. This
raises the question of whether metformin
alters human microbiota metabolism as
well, in particular folate and methionine
cycles, and if this contributes to the effi-
cacy of metformin therapy and/or its
side effects in humans.REFERENCES
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